Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (251-260 of 471) with videos related to

Pageof 48
Sort By:
Blood|January 12, 2012
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogeneticsShaji Kumar, Rafael Fonseca, Rhett P Ketterling, et al.
American Journal of Hematology|June 30, 2019
Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosisSurbhi Sidana, M Hasib Sidiqi, Angela Dispenzieri, et al.
Leukemia|November 12, 2021
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
American Journal of Hematology|July 6, 2019
Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosisAbdullah S Al Saleh, M Hasib Sidiqi, Surbhi Sidana, et al.
American Journal of Hematology|October 16, 2019
Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patientsAbdullah S Al Saleh, M Hasib Sidiqi, Angela Dispenzieri, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantationSandra M S Herrmann, Morie A Gertz, Mark D Stegall, et al.
Leukemia|October 12, 2021
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaSaurabh Zanwar, Matthew Ho, Prashant Kapoor, et al.
Blood Advances|July 1, 2025
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysisEli Muchtar, Angela Dispenzieri, Francis K Buadi, et al.
Leukemia|November 28, 2019
Revisiting complete response in light chain amyloidosisSurbhi Sidana, Angela Dispenzieri, David L Murray, et al.
Leukemia|June 17, 2024
Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessmentJean-Sébastien Claveau, David L Murray, Angela Dispenzieri, et al.
Pageof 48

Showing results (251-260 of 471) with videos related to

Sort By:
Pageof 48
Blood|January 12, 2012
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogeneticsShaji Kumar, Rafael Fonseca, Rhett P Ketterling, et al.
American Journal of Hematology|June 30, 2019
Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosisSurbhi Sidana, M Hasib Sidiqi, Angela Dispenzieri, et al.
Leukemia|November 12, 2021
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
American Journal of Hematology|July 6, 2019
Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosisAbdullah S Al Saleh, M Hasib Sidiqi, Surbhi Sidana, et al.
American Journal of Hematology|October 16, 2019
Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patientsAbdullah S Al Saleh, M Hasib Sidiqi, Angela Dispenzieri, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantationSandra M S Herrmann, Morie A Gertz, Mark D Stegall, et al.
Leukemia|October 12, 2021
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaSaurabh Zanwar, Matthew Ho, Prashant Kapoor, et al.
Blood Advances|July 1, 2025
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysisEli Muchtar, Angela Dispenzieri, Francis K Buadi, et al.
Leukemia|November 28, 2019
Revisiting complete response in light chain amyloidosisSurbhi Sidana, Angela Dispenzieri, David L Murray, et al.
Leukemia|June 17, 2024
Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessmentJean-Sébastien Claveau, David L Murray, Angela Dispenzieri, et al.
Pageof 48